Abstract: Proteolytic processing of the amyloid precursor protein (APP) leads to amyloid-β (Aβ) peptides. So far, the mechanism of APP processing is insufficiently characterized at the molecular level. Whereas the knowledge of Aβ generation by several proteases has been expanded, the contribution of the Kunitz-type protease inhibitor domain (KPI) present in two major APP isoforms to the complex proteolytic processing of APP is poorly understood. In this study, we have identified KPI-containing APP as a very potent, slow-binding inhibitor for the membrane-bound proteolytic regulator of iron homeostasis matriptase-2 by forming stable complexes with its target protease in HEK cells. Inhibition and complex formation depend on the intact KPI domain. By inhibiting matriptase-2, KPIcontaining APP is protected from matriptase-2-mediated proteolysis within the Aβ region, thus preventing the generation of N-terminally truncated Aβ.
Introduction
Matriptase-2 (MT2; the corresponding gene name is TMPRSS6) was shown to be a critical proteolytic regulator controlling iron metabolism. This was evidenced by patients with mutations in TMPRSS6 suffering from iron-refractory iron deficiency anemia (IRIDA) (Finberg et al., 2008) and by murine models with an anaemic and iron deficient phenotype (Du et al., 2008; Folgueras et al., 2008; Finberg et al., 2010) . It has been demonstrated that matriptase-2 downregulates hepcidin expression via bone morphogenetic protein (BMP)/sons of mothers against decapentaplegic (SMAD) signaling, probably by cleaving the BMP co-receptor hemojuvelin which was shown in vitro (Silvestri et al., 2008; Maxson et al., 2010) . Matriptase-2-mediated hemojuvelin cleavage in vivo is under investigation (Krijt et al., 2011) .
Matriptase-2 belongs to the type II transmembrane serine proteases (TTSPs) within the superfamily of trypsinlike serine proteases and was discovered in 2002 (Hooper et al., 2001; Velasco et al., 2002) . This protease comprises a short N-terminal cytoplasmic tail and a large extracellular domain, the latter is divided into the stem region with the sea urchin sperm protein, enteropeptidase, agrin (SEA) domain, two CUB domains and three low density lipoprotein (LDL) receptor class A domains, and the protease domain. Matriptase-2 shares high similarities to the close homologue matriptase, involved in epidermal differentiation, which is tightly regulated by its cognate Kunitz-type inhibitor hepatocyte growth factor activator inhibitor-1 (HAI-1) (Lin et al., 1999; Bugge et al., 2007; Miller and List, 2013) . Recently, we have found matriptase-2 to be inhibited by Kunitz-type inhibitor hepatocyte growth factor activator inhibitor-2 (HAI-2) in a cell system co-expressing both proteins (Maurer et al., 2013) .
In this study, the amyloid precursor protein (APP) was identified as another candidate inhibitor for matriptase-2 in cell-free and cell-based assays. APP is an ubiquitously expressed type I transmembrane protein discovered in 1987 (Goldgaber et al., 1987) with a still unknown physiological function. It is one of the most studied proteins as it has been implicated in the pathogenesis of Alzheimer's disease (AD) (LaFerla and Oddo, 2005; Zheng and Koo, 2011) . One of the pathologic hallmarks of AD is the accumulation of insoluble, extracellular amyloid plaques in the brain which are mainly composed of Aβ peptides derived from APP processing (Selkoe 1991) . In the amyloidogenic pathway, cleavage of APP by β-site APP-cleavage enzyme 1 (BACE1) generates a membrane-bound C-terminal fragment (CTFβ) which is subsequently cleaved by the γ-secretase complex generating neurotoxic Aβ peptides (Vassar et al., 1999; Sastre et al., 2001) . The generation of Aβ peptides is prevented by processing of APP via the non-amyloidogenic pathway in which the α-secretase cleaves within the Aβ domain producing an extracellular soluble form of APP (sAPPα) with neuroprotective properties (Sisodia 1992) .
Three major isoforms APP695, APP751 and APP770 are known. The latter two contain a Kunitz-type protease inhibitor domain (KPI) of 51 amino acids located in the middle of the ectodomain and are widely expressed in non-neuronal cells whereas APP695, lacking the KPI domain, is the predominant isoform found in brain. The amino acid sequence of APP770 is depicted in Figure 1A . The KPI domain of APP was shown to inhibit serine proteases in vitro such as trypsin and chymotrypsin (Van Nostrand et al., 1989; Van Nostrand et al., 1990; Bhasin et al., 1991; Shimokawa et al., 1993) , and factors XIa and IXa (Schmaier et al., 1995) .
In this study, the inhibitory potential of KPI-containing APP towards matriptase-2 was determined by kinetic analysis. Additionally, the impact of KPI-mediated matriptase-2 inhibition on APP processing was characterized. Our results indicate that the KPI domain protects APP from being degraded by matriptase-2. Uninhibited matriptase-2 processes APP to generate N-terminally truncated Aβ(6-40) in cell culture experiments.
Results

APP inhibits matriptase-2 in a cell-based system
Recently, we have found matriptase-2 to be inhibited by the Kunitz-type inhibitor HAI-2 in a cell system co-expressing ). (B) The type I transmembrane protein APP770 was cloned as a fusion construct with an N-terminal Strep-tag (Strep-APP770), the type II transmembrane protein matriptase-2 was cloned as a fusion construct with a C-terminal Myc-and His-tag (MT2-MycHis). After expression, all tags are exposed at the cell surface. Cat, serine protease catalytic domain; CUB, complement factor C1s/1r, urchin embryonic growth factor, BMP domain; L, low-density lipoprotein receptor class A domain; SEA, sea urchin sperm protein, enteropeptidase, agrin domain; TM, transmembrane domain. both proteins (Maurer et al., 2013) . In order to validate whether KPI-containing APP inhibits matriptase-2 we coexpressed APP770 in HEK cells stably transfected with matriptase-2. For this, a vector encoding matriptase-2 C-terminally fused to a Myc-and His-tag and a vector encoding isoform APP770 containing KPI N-terminally fused to a Strep-tag were used (Figure 1 ). Matriptase-2 activity was measured in membrane fractions as well as concentrated conditioned media derived from matriptase-2-transfected HEK cells with the peptide substrate Boc-QAR-para-nitroanilide ( Figure 2A ) as reported previously . In contrast, HEK-mock and APP770 expressing cells did not display any measurable activity.
Interestingly, matriptase-2 activity was drastically diminished after co-expressing APP770 and matriptase-2 indicating that APP770 bears the potential to inhibit matriptase-2 proteolytic activity in a cell-based system.
Inhibition of matriptase-2 by APP770 was also demonstrated by determining the activity of cell surface-associated matriptase-2 on intact HEK-MT2-Myc-His cells in the presence of recombinant soluble APP770 (sAPP770). For this, sAPP770 was purified from conditioned media of transfected HEK cells ( Figure S1A ). While HEK-mock cells did not show any activity, the used fluorogenic peptide substrate Boc-QAR-7-amido-4-methylcoumarin (AMC) was cleaved by HEK-MT2-Myc-His cells with a more moderate (A) HEK-mock and HEK-MT2-Myc-His cells either alone or transiently transfected with pEXPR-Strep-APP770 were cultured for 2 days with Opti-MEM. Total protein from membrane fractions (20 μg; MF) or concentrated conditioned media (5 μg; CM) was incubated with 200 μm Boc-QAR-para-nitroanilide as a substrate. The release of para-nitroaniline was monitored at a wavelength of 405 nm for 20 min at 37°C. The resulting activities were normalized to proteolytic activity in concentrated media derived from HEK-MT2-Myc-His cells and measured in duplicate in at least two independent experiments. (B) Matriptase-2 activity was measured at the surface of intact HEK-MT2-Myc-His cells or HEK-mock cells grown on a 96-well plate. The reaction was started by adding 40 μm of the fluorogenic substrate Boc-QAR-AMC and 30 nm of purified sAPP770 and subsequently followed at 37°C for 50 min. Data points for HEK-mock and HEK-MT2-Myc-His cells were shown previously (Beckmann et al., 2016) . (C) Different amounts of purified sAPP770 were incubated with conditioned media derived from matriptase-2-expressing HEK cells in the presence of 40 μm of the fluorogenic substrate Boc-QAR-AMC. The release of 7-amino-4-methylcoumarin from the fluorogenic substrate was monitored with an excitation wavelength of 340 nm and emission wavelength of 460 nm over 50 min at 37°C. ) rate constants for inhibitor association/dissociation were obtained.
activity in the presence of 30 nm sAPP770 ( Figure 2B ). By applying these two different methods for assaying matriptase-2 activity, the Kunitz-type inhibitor APP770 has been newly identified as an inhibitor of matriptase-2.
APP770 acts as a potent, slow-binding inhibitor for matriptase-2
In a next step, we characterized the inhibitory potency of APP770 against matriptase-2. For this, purified recombinant sAPP770 was incubated with conditioned media derived from matriptase-2-expressing HEK cells in the presence of the fluorogenic substrate Boc-QAR-AMC. Efficient shedding of active matriptase-2 allows the usage of concentrated media for enzyme kinetics (Sisay et al., 2010; Stirnberg et al., 2010; Dosa et al., 2012; Maurer et al., 2012) . The progress curves in the presence of different inhibitor concentrations were non-linear in the pre-equilibrium phase and approached linearity to achieve the binding equilibrium ( Figure 2C ) rate constants for inhibitor association/dissociation were obtained. The inhibition constant K i of 0.66±0.02 nm was calculated from the steady state rates of the progress curves, which were plotted versus the inhibitor concentration ( Figure 2D ) to obtain the IC 50 value, from which the K i value was calculated. In summary, the kinetic analyses confirmed a reversible, slow-binding mode of interaction indicating that sAPP770 binds to the active site of matriptase-2 in a substrate-like manner as proposed for Kunitz-type inhibitors (Eigenbrot et al., 2010; Farady and Craik, 2010) . The same analysis was performed with the purified isoform sAPP751 also containing KPI. This isoform exhibited a K i value in exactly the same low nanomolecular range as sAPP770 ( Figure S2A and B) whereas sAPP695 and sAPP770
ΔKPI
, both containing no KPI domain, did not inhibit matriptase-2 ( Figure S2C and D). In conclusion, the two KPI-containing sAPP770 and sAPP751 have equal inhibitory potencies towards matriptase-2 while KPI-lacking sAPP695 and sAPP770 ΔKPI were ineffective.
Matriptase-2 forms complexes with APP770
As Kunitz-type inhibitors are known to form stable, SDSresistant complexes with their target proteases, formation of complexes was analyzed by Western blotting (WB) in HEK cells transfected with matriptase-2 and APP770. Matriptase-2 was detected with a molecular weight of ca. 120 kDa in membrane fractions derived from HEK cells expressing matriptase-2 by the use of the c-Myc antibody after separating the proteins under reducing and nonreducing conditions (Figure 3A and B; left panels; lanes 4 and 5). Matriptase-2 undergoes a complex auto-processing mechanism resulting in cell surface release of a two-chain form Jiang et al., 2014) . After its synthesis as a membrane-bound, inactive one-chain zymogen of ca. 120 kDa, matriptase-2 is shed into the surrounding medium as an activated two-chain form of about 55 kDa comprising the protease domain of ca. 30 kDa tethered via a conserved disulfide bond to a portion of the stem region . For this reason, the 30 kDa protease domain was detectable in the conditioned media of matriptase-2-expressing cells after separating the samples under reducing conditions ( Figure 3A ; right panel; lanes 8 and 9) whereas under non-reducing conditions the disulfide-linked two-chain form of matriptase-2 of ca. 55 kDa was visible ( Figure 3B ; right panel; lanes 8 and 9). Interestingly, after co-expressing APP770, two additional matriptase-2-specific signals occurred in the conditioned media of ca. 130 and 170 kDa ( Figure 3B ; right panel; lane 9, asterisks) indicating that matriptase-2 is bound to interaction partners that are presumably distinct shed forms of APP770. APP-specific signals were detected by the use of StrepTactin AP conjugate in membrane fractions and in conditioned media of APP770-transfected cells of ca. 120 kDa (Figure 3C and D; left and right panels; lanes 3, 5, 7 and 9). The presence of soluble APP in conditioned media indicated cell surface release of APP770 in our cell system generated by α-secretase (sAPPα). Notably, after separating proteins of conditioned media under non-reducing conditions, a further signal of ca. 170 kDa was visible after co-expressing matriptase-2 ( Figure 3D ; right panel; lane 9, asterisk) again demonstrating that APP770 is bound to matriptase-2. Beside this, an additional band of ca. 95 kDa suggested that matriptase-2 is presumably able to cleave APP770. These results show that matriptase-2 and APP770 interact to form stable, SDS-resistant complexes. APP770 was confirmed as an interaction partner of matriptase-2 by purification of c-Myc-tagged matriptase-2 via the affinity to Strep-tagged APP770 bound to immobilized StrepTactin ( Figure 4 ).
Matriptase-2 inhibition by APP770 depends on intact KPI
We next analyzed whether the inhibitory potential of APP770 against matriptase-2 and/or formation of the matriptase-2/APP complex depends on KPI of APP770. For this purpose, different mutated variants of APP770 were co-expressed in matriptase-2-transfected cells in which the whole KPI (ΔKPI) was deleted or a specific arginine Conditioned media (400 μg total protein) of HEK-MT2-Myc-His or HEK-mock cells either untreated or transiently transfected with pEXPR-Strep-APP770, were subjected to affinity chromatography using the Strep-tag purification technique. Elution fractions were analyzed by Western blotting using either the anti-c-Myc antibody or the Strep-Tactin alkaline phosphatase conjugate. AP, Affinity purification.
residue was mutated. The canonical active site of Kunitzdomain containing proteins was identified as Arg 260 in case of Kunitz domain I of HAI-1 (Lin et al., 2008 ) that assigned the inhibitory specificity against trypsin-like serine proteases which are characterized to show a clear preference for arginine residues in P1 position. Therefore, the corresponding Arg 301 in KPI of APP770 was mutated to Glu in R301E ( Figure 1A ). As expected, APP770 with mutated ΔKPI and R301E failed to inhibit matriptase-2 to a similar extent as wild type (WT) APP770 ( Figure 5A ). This is in line with the absence of an inhibitory potency of purified KPI-lacking sAPP695 or sAPP770 ΔKPI towards matriptase-2 ( Figure S2C and D) . In sum, these results show that KPI and specifically the amino acid Arg 301 are critical in determining the inhibitory potential of APP against matriptase-2.
Formation of APP/matriptase-2 complexes depends on intact KPI
Additionally, we analyzed whether the lack of inhibitory capacity of the APP770 mutants correlates with the inability to form stable complexes with matriptase-2. For this reason, protein samples were separated under non-reducing conditions prior to Western blotting to maintain protein/protein interactions. In conditioned media, the soluble WT and mutated APP770 fragments of ca. 120 kDa appeared ( Figure  5B ; lanes 3, 5 and 7) indicating that the mutated APP770 variants were released from the cell surface. Again, coexpression of WT APP770 with matriptase-2 revealed the 170 kDa-complex and the cleaved 95 kDa-fragment beside the 120 kDa-fragment ( Figure 5B ; lane 4; 170 kDa-complex marked with an asterisk). Notably, the complex at 170 kDa was absent in the generated APP770 mutants ( Figure 5B ; lanes 6 and 8). Moreover, co-expression of matriptase-2 with mutated APP770 completely abolished the 120 kDafragment and increased the signal of the cleaved 95 kDafragment ( Figure 5B ; lanes 6 and 8). Expression of WT and mutated APP770 at ca. 120 kDa was confirmed in membrane fractions ( Figure 5C ; lanes 3-8).
Using a c-Myc antibody, matriptase-2 was visible at 55 kDa in conditioned media of single transfected cells ( Figure 5D ; lane 2). In co-transfected cells matriptase-2-specific signals occurred at ca. 55, 130 and 170 kDa ( Figure 5D ; lane 4; 170 and 130 kDa-complexes marked with asterisks). After co-expressing the mutated APP770 variants, complexes at ca. 130 and 170 kDa were missing ( Figure 5D ; lanes 6 and 8) reflecting the results obtained by APP detection. In membrane fractions, matriptase-2 was again visible at ca. 120 kDa ( Figure 5E ; lanes 2, 4, 6 and 8). These results indicate that the mutated variants of APP770 being affected in their KPI domain obviously failed to form complexes with matriptase-2 according to their impaired inhibitory potential against matriptase-2.
Matriptase-2 generates truncated versions of APP
Expression of matriptase-2 resulted in the secretion of an additional fragment of APP770 into the conditioned media that migrates below (~95 kDa) the secreted sAPPα fragment generated by α-secretase (~120 kDa) ( Figure  3D ; right panel; lane 9 and Figure 5B ; lane 4). Thus, WT APP770 did not serve merely as an inhibitor but also as a substrate of matriptase-2. As the Strep-tag fused to the N-terminus was used for detection of APP ( Figure 1B ), matriptase-2 is able to generate C-terminally truncated versions of soluble APP770 in this cell system. Furthermore, after diminishing the inhibitory potential of APP770 by expressing the mutated versions affected in KPI, the apparent molecular mass of secreted APP770 shifted from 120 kDa to 95 kDa ( Figure 5B ; lanes 6 and 8). These results show that matriptase-2 cleaves APP efficiently in case it is not inhibited by the APP KPI domain. In summary, the KPI domain is likely to protect APP from being degraded by matriptase-2 in our cell system.
In order to analyze if matriptase-2 is involved in the generation of Aβ peptides, two quenched fluorogenic peptide substrates, M2460 and M2465, derived from amino acids 667-676 of human APP770 WT (M2460) and human APP770 Swedish mutant (M2465) representing the β-secretase cleavage site ( Figure 6A ) were tested for their susceptibility to be cleaved by matriptase-2. Both substrates were efficiently cleaved by matriptase-2 in conditioned media of HEK-MT2-Myc-His cells ( Figure 6B ). As mentioned above, matriptase-2 has a clear preference to cleave after positively charged amino acids. Figure 1A) . Therefore, we analyzed the generation of secreted Aβ peptides in dependence on matriptase-2 expression using WT APP770, APP770
ΔKPI and double mutant APP770
ΔKPI/R676E
. The Aβ peptides were immunoprecipitated from conditioned media of transfected HEK cells with antibody 4G8 recognizing an epitope within amino acids 18-22 of Aβ ( Figure 1A ) prior to immunoblotting with this antibody. As shown in Figure  7A (lower panel, lanes 1, 3 and 5) Aβ was generated after expression of APP. Aβ was also produced in the presence of matriptase-2 ( Figure 7A, lower panel, lane 2) . However, after co-expression of matriptase-2 and APP770
ΔKPI a shift to a smaller Aβ peptide variant was observed ( Figure 7A , lower panel, lane 4) indicating that matriptase-2 cleaves APP within the Aβ domain. In accord with this result, a larger CTF was additionally present in membrane fractions of these cells ( Figure 7A , middle panel, lane 4). Assuming that the shorter version of the CTFs was generated by the α-secretase cleavage (CTFα) the larger matriptase-2 generated version (CTF MT2 ) occurred by cleavage at Arg 676 . This is further supported by the absence of the higher molecular weight CTF MT2 in APP770
ΔKPI/R676E and matriptase-2-expressing cells ( Figure 7A , middle panel, lane 6). However, a shift to a smaller Aβ peptide was still observable in this sample although the putative matriptase-2 cleavage site Arg 676 was mutated indicating that matriptase-2 can additionally cleave Aβ at another position.
Because antibody 4G8 not only detects Aβ, but also the p3 peptide that is generated by the α-secretory processing and subsequent cleavage of the CTF by γ-secretase we have also used the N-terminal neoepitope-specific antibody 82E1 recognizing amino acids 1-5 of the Aβ peptide. Again, detection of Aβ was possible after transfection of APP ( Figure 7B , lower panel, lanes 3 and 5) verifying the generation of Aβ in these cells. Interestingly, co-expression of APP770 ΔKPI and matriptase-2 completely abolished the Aβ signal detectable by antibody 82E1 ( Figure 7B , lower panel, lane 6) although Aβ was present in this sample as shown by using antibody 4G8 ( Figure 7A , lower panel, lane 4), thereby confirming that matriptase-2 cleaves within the N-terminal region of Aβ. The absence of the signal after co-expressing matriptase-2 and the mutated variant APP770 ΔKPI/R676E ( Figure 7B , lower panel, lane 8) may result from the inability to detect the mutated neoepitope. Accordingly, the Aβ signal in lane 7 could be derived from endogenously expressed APP which was also detectable as shown in lane 1 ( Figure 7B , lower panel). Cleavage at Arg 676 by matriptase-2 was further indicated by the absence of sAPPα in conditioned media of cells co-expressing matriptase-2 and the mutated variant APP770 ΔKPI using antibody 6E10 ( Figure 7B , upper panel, lane 6). This antibody recognizes an epitope within amino acids 3-8 of the Aβ region. We postulated that after cleavage at Arg 676 , sAPP MT2 was generated which escaped detection by antibody 6E10. The absence of the signal after co-expressing matriptase-2 and the mutated variant APP770
ΔKPI/R676E ( Figure 7B , upper panel, lane 8) may again result from the inability to detect the mutated epitope and the presence of the signal in lane 7 may be derived from Aβ generated from endogenously expressed WT APP.
To verify Aβ processing by matriptase-2 at position Arg 676 in our cell-based system, mass spectrometric analyses were performed with samples derived from conditioned media of HEK-mock and HEK-MT2-Myc-His cells transfected with the mutated variant APP770 ΔKPI after immunoprecipitation (IP) with antibody 4G8. These samples were already analyzed by WB resulting in a shift to a smaller Aβ peptide in the presence of matriptase-2 ( Figure 7A, lower panel, lanes 3 and 4) . MALDI-TOF analyses revealed the presence of Aβ(1-40) derived from cells expressing APP770 ΔKPI (Figure 8 ). Concurrently with the observed shift to a smaller Aβ peptide variant by Western blotting, Aβ (6-40) was detectable by MALDI-TOF analyses instead of Aβ(1-40) after simultaneous expression of APP770 ΔKPI and matriptase-2 undoubtedly confirming the cleavage site at position Arg 676 targeted by matriptase-2. Additionally, Aβ(5-40) disappeared after co-expression of matriptase-2, possibly due to degradation to Aβ(6-40) by matriptase-2 (Figure 8 ). In HEK-mock cells Aβ(1-37/38) was detected (Figure 8 , upper spectrum), presumably degraded to Aβ(6-37/38) in the presence of matriptase-2 ( Figure S3) .
In a further experiment synthetic Aβ(1-42) was incubated with recombinant matriptase-2. As a control, synthetic Aβ(1-42) was incubated alone. While MALDI-TOF measurements revealed the presence of full length Aβ(1-42) in both samples ( Figure S4 ), the application of LC-MS analysis identified Aβ peptides cleaved by matriptase-2. Indeed, Aβ(6-17) and Aβ(6-28) were found (Table 1) 
Discussion
Whilst the proteases involved in APP processing have been studied intensively during the past years, the mechanism of controlling the activity of processing proteases due to the action of APP itself is largely unknown. APP exists in three major isoforms with unknown functions from which two of them comprise a KPI domain bearing the potential to inhibit several serine proteases (Van Nostrand et al., 1989 , 1990 Bhasin et al., 1991; Shimokawa et al., 1993; Schmaier et al., 1995) . In our study, we have identified KPI-containing APP770 as a very potent inhibitor of the serine protease matriptase-2 by forming stable complexes depending on one critical arginine residue in APP, Arg 301 in a transfected cell system. Due to its high inhibitory potential, KPI-containing APP770 is protected from being degraded by the overexpressed matriptase-2. Remarkably, APP770 did not inhibit the intrinsic activity of matriptase-2 zymogen as the two processing events catalyzed by matriptase-2 itself, activation and shedding , were detectable by the presence of a 30 kDa-fragment in conditioned media of matriptase-2 and APP770 expressing HEK cells ( Figure 3A , lane 9). This could be due to a lower affinity of KPI-containing APP770 for the inactive zymogen than for the activated protease.
Interestingly, in our cell system APP770 serves as an inhibitor and likewise as a substrate depending on the presence of the KPI domain. The deletion of the KPI domain changed the role of APP from being an inhibitor to being a substrate for matriptase-2. Matriptase-2 hydrolyzes peptide bonds after basic amino acids with a clear preference for arginine over lysine in P1 position (Velasco et al., 2002) . Accordingly, we could identify Arg 676 (corresponding to Aβ5) within the N-terminal region of the Aβ domain which is cleaved by matriptase-2 by MALDI-TOF analyses after co-expressing APP770 ΔKPI and matriptase-2. Other sites, probably Lys 687 (corresponding to Aβ16) which is the α-secretase cleavage site and Lys 699 (corresponding to Aβ28), may also be targeted by matriptase-2 as shown by LC-MS analysis of a synthetic Aβ peptide after incubation with recombinant matriptase-2 (Table 1) and by Western blot analysis of Aβ after co-expressing APP770
ΔKPI/R676E and matriptase-2 ( Figure 7A, lower panel, lane 6) . The shift to a smaller Aβ peptide variant in this sample indicated the presence of at least one additional cleavage site beside Arg 676 that is presumably Lys
699
. Cleavage at this site would generate Aβ(1-28) with a similar molecular weight like Aβ(6-40).
Additionally, matriptase-2 seems to target APP770 beside the Aβ domain. After co-expressing matriptase-2 and KPI-containing APP770, a smaller complex of 130 kDa appeared beside the 170 kDa-complex as observed by the use of the c-Myc-antibody ( Figure 3B, lane 9) . Because this smaller 130 kDa-complex could not be seen after detection of Strep-tagged APP770 ( Figure 3D, lane 9) , APP770 is presumably N-terminally truncated resulting in the loss of the Strep-tag.
A proposed model of matriptase-2 mediated processing of APP770 is shown in Figure 9 . In our cell system, processing of KPI-containing APP770 can occur predominantly by α-secretase described as the non-amyloidogenic pathway producing sAPPα detectable in conditioned media and CTFα detectable in membrane fractions. The occurrence of these APP fragments, sAPPα and CTFα, is independent on matriptase-2 co-expression. Smaller amounts of APP770 can be processed by the amyloidogenic pathway since Aβ, presumably Aβ(1-40), was detectable in conditioned media. If APP is expressed without the KPI domain matriptase-2 becomes active and catalyzes the cleavage after position Arg
676
. The cleavage may occur in full length APP generating sAPP MT2 and CTF MT2 . The latter can be converted to Aβ(6-40) by the γ-secretase. Matriptase-2 cleavage may also occur in CTFβ liberating CTF MT2 , in Aβ(1-40) liberating Aβ(6-40) and in sAPPα liberating sAPP MT2 . As a consequence, in APP770 ΔKPI and matriptase-2 co-expressing cells, sAPP MT2 , CTFα, CTF MT2 and Aβ(6-40) were present in detectable levels.
Taken together, we have demonstrated for the first time that the KPI domain determines the susceptibility of APP to proteolytic cleavage by the serine protease matriptase-2 in HEK cells. The proteolysis of APP by matriptase-2 generating, amongst others, N-terminally truncated Aβ peptides solely depends on the presence of KPI. Future experiments are necessary to analyze the biological relevance of matriptase-2-mediated APP processing. Additionally, it has to be elucidated whether KPI-containing APP is involved in iron homeostasis by regulating matriptase-2 activity. A link between APP and iron homeostasis was already suggested by describing an iron-responsive element in the 5′-untranslated Figure S4 .
Position in Aβ
Aβ Aβ+MT2 The single-letter amino acid code is used. APP can be processed either by α-or β-secretase producing extracellular soluble N-terminal fragments (sAPPα or sAPPβ) and membranebound C-terminal fragments (CTFα or CTFβ). Without the KPI domain APP can be additionally processed by matriptase-2 producing sAPP MT2 and CFT MT2 . CTFs can be further degraded by the action of γ-secretase generating the small p3 fragment, Aβ(1-40) or Aβ(6-40). The recognition site for antibody 4G8 is indicated by a red cross mark. Cleavage sites for α-, β-and γ-secretases are indicated by a gray dash line, the cleavage site for matriptase-2 is indicated by a red line. All cleavage sites within full length APP are also indicated by amino acid numbers (numbering corresponds to Aβ peptide).
region of the APP transcript (Rogers et al., 2002) and by reporting an interaction of APP and the iron exporter ferroportin (Wong et al., 2014) . Recently, matriptase-2 was identified as a cell surface activator of metalloprotease meprin β thereby enhancing APP shedding (Jäckle et al., 2015) .
Materials and methods
Cell lines and culture conditions
Human embryonic kidney (HEK) 293 cells (Graham et al., 1977) were cultured in Dulbecco's Modified Eagle's Medium. Huh-7 cells were cultured in RPMI medium. Cells were cultured under a humidified atmosphere of 5% CO 2 at 37°C. Both media were supplemented with penicillin (100 U/ml), streptomycin (100 μg/ml), and fetal bovine serum (FBS) (10%). Additionally, Huh-7 cells were cultured in medium supplemented with glutamine (2 mm) and non-essential amino acids (0.1 mm; all substances and media from Life Technologies, Karlsruhe, Germany).
Cloning
The construction of the expression plasmids pcDNA4 and pcDNA4-MT2-Myc-His, and the generation of stably transfected HEK-MT2-MycHis cells were described previously .
For the generation of all other plasmids total mRNA was isolated from Huh-7 cells with TRIZOL-Reagent (Life Technologies) and transcribed into cDNA using Omniscript RT kit (Qiagen, Hilden, Germany) and Oligo(dT) primer (Life Technologies) according to the instruction manuals. For the expression of APP770 (Leu 18 -Asn
770
) with a Strep-tag at the N-terminus, the whole APP open reading frame was amplified using primers 5′-GCT CCC GGT CTC TGC GCC CTG GAG GTA CCC ACT GAT GG-3′ and 5′-GCT CCC GGT CTC TGG CCC TAG TTC TGC ATC TGC TCA AAG-3′ (BsaI recognition sites in bold, APP cDNA underlined) digested with BsaI and ligated into the BsaI-digested expressing vector pEXPR-IBA44 (IBA, Göttingen, Germany) to generate pEXPR-Strep-APP770.
This vector was used to generate pEXPR-Strep-APP770
ΔKPI encoding APP770 without the KPI domain by splicing by overlapping extension PCR with primers 5′-GCT CCC GGT CTC TGC GCC CTG GAG GTA CCC ACT GAT GG-3′ and 5′-CTT TGG GAC ATG GCG CTG CCC ACC TCT CGA ACC ACC TCT T-3′ for the amplification of the APP-encoding cDNA upstream of the KPI-encoding sequence, and 5′-AAG AGG TGG TTC GAG AGG TGG GCA GCG CCA TGT CCC AAA G-3′ and 5′-GCT CCC GGT CTC TGG CCC TAG TTC TGC ATC TGC TCA AAG-3′ for the amplification of the cDNA downstream of the KPI-encoding sequence. The vector pEXPR-Strep-APP770 was also subjected to site directed mutagenesis with GeneArt Site-Directed Mutagenesis System (Life Technologies) according to the instruction manual using primers 5′-CGA GAC GGG GCC GTG CGA AGC AAT GAT CTC-3′ and 5′-GCA CGG CCC CGT CTC GGC TTG TTC AGA G-3′ to generate pEXPR-Strep-APP770
R301E
. The vector pEXPR-Strep-APP770
ΔKPI was subjected to site directed mutagenesis using primers 5′-GGA TGC AGA ATT CGA ACA TGA CTC AGG ATA TG-3′ and 5′-CAT ATC CTG AGT CAT GTT CGA ATT CTG CAT CC-3′ to generate pEXPR-Strep-APP770
ΔKPI/R676E .
Matriptase-2 activity assay of concentrated media and membrane fractions
Proteolytic activity measurements were performed with 5 μg total protein from concentrated media or 20 μg total protein of membrane fractions from HEK-mock or HEK-MT2-Myc-His cells either alone or transiently transfected with pEXPR-Strep-APP770, pEXPR-Strep-APP770 ΔKPI or pEXPR-Strep-APP770 R301E using 200 μm Boc-QAR-paranitroanilide (Bachem, Bubendorf, Switzerland) as described previously .
Purification of sAPP770
HEK cells were grown in 175 cm 2 -flasks. After transfection with 84 μg pEXPR-Strep-APP770, cells were cultured for 2 days with Opti-MEM. sAPP770 was isolated from the concentrated conditioned medium by affinity chromatography using the Strep-Tactin Sepharose column (IBA) following the manufacturer's instructions. Purity of isolated sAPP770 was confirmed by SDS-PAGE ( Figure S1A ) and concentration was determined by Bradford assay (Roti-Nanoquant; Carl Roth, Karlsruhe, Germany).
Matriptase-2 activity assay of intact cells
For measuring matriptase-2 proteolytic activity of intact cells, HEK-MT2-Myc-His cells or HEK-mock cells were grown on the surface of a 96-well plate. For this purpose, the cells were incubated in 200 μl of Dulbecco's modified Eagle's (DMEM)-medium (Gibco Life Technologies) to a confluence of approximately 70% under a humidified atmosphere of 5% CO 2 at 37°C. After removing DMEM, assay buffer (50 mM Tris-HCl, 150 mm NaCl, pH 8.0) and 30 nm of purified sAPP770 were added to each well. The reaction was started immediately by adding 0.8 μl of the fluorogenic peptide substrate Boc-QAR-AMC (10 mm stock solution). The final concentration of the substrate was 40 μm. The reaction was followed at 37°C for 50 min with an excitation wavelength of 340 nm and emission wavelength of 460 using the Fluostar Optima Plate Reader (BMG Labtech, Offenburg, Germany).
Kinetics of matriptase-2 inhibition
Inhibition assays of matriptase-2 in concentrated media of stably transfected HEK-MT2-Myc-His cells in the presence of different concentrations of purified APP were performed by monitoring the release of 7-amino-4-methylcoumarin from the fluorogenic substrate Boc-QAR-AMC using Fluostar Optima Plate Reader (BMG Labtech). Reactions were monitored with an excitation wavelength of 340 nm and emission wavelength of 460 nm over 50 min at 37°C in a total volume of 200 μl assay buffer (50 mm Tris-HCl, 150 mm NaCl, pH 8.0) in the presence of 40 μm substrate and different APP concentrations (2-10 nm).
Progress curves of the reactions were analyzed by nonlinear regression using the slow-binding equation (Dosa et al., 2012) . The obtained k obs values were replotted versus the inhibitor concentrations resulting in a linear correlation where k on ′ was given by the slope and k off by the ordinate-intercept. The k on value was calculated using the equation Fourty-eight hours after transfection, culture supernatants were concentrated and membrane fractions and lysates were isolated as described previously ). An amount of 30 μg total protein from concentrated media, membranes or lysates were separated by SDS-PAGE (10% acrylamide) under non-reducing or reducing conditions and subjected to Western blot analysis using monoclonal c-Myc antibody (clone 9E10; diluted 1:200) (Evan et al., 1985) or monoclonal anti-APP antibodies (4G8, diluted 1:1000; 6E10, diluted 1:100; both from Covance, Princeton, NJ, USA) and alkaline-phosphataseconjugated secondary antibody (diluted 1:10 000; Novagen, Merck, Darmstadt, Germany). Strep-tagged APP was also detected by using Strep-Tactin alkaline phosphatase conjugate (IBA). Detection was performed with NBT/BCIP (Nitro Tetrazolium Blue chloride/5-bromo-4-chloro-3-indolyl phosphate; Sigma-Aldrich, St. Louis, MO, USA). Transfer of proteins onto nitrocellulose membranes was validated by Ponceau S staining.
SDS-PAGE and immunoblotting
Co-purification of matriptase-2/APP complexes by affinity chromatography
For detection of complexes formed by matriptase-2/APP770, 400 μg total protein of conditioned media derived from HEK-MT2-Myc-His or HEK-mock cells transiently transfected with pEXPR-Strep-APP770, were subjected to affinity chromatography using the Strep-Tactin Sepharose column (IBA) according to the manufacturer's instructions. Elution fraction 3 was concentrated and subsequently analyzed by WB under reducing conditions using either the Strep-Tactin alkaline phosphatase conjugate for detection of APP770 or the c-Myc antibody for detection of matriptase-2.
Kinetics of APP cleavage by matriptase-2
To determine specific matriptase-2 cleavage sites within the APP amino acid sequence, two commercially available substrates covering the region from amino acids 667 to 676 harboring the β-secretase cleavage site were used (M2460, M2465; Bachem). Reactions were monitored with an excitation wavelength of 340 nm and emission wavelength of 460 nm over 20 min at 37°C in a total volume of 200 μl in the presence of 40 μm substrate and conditioned media from matriptase-2-expressing HEK cells or of conditioned media from HEKmock cells. Assay buffer was 50 mm Tris-HCl, 150 mm NaCl, pH 8.0.
Detection of Aβ
Secreted Aβ was detected with monoclonal antibodies 4G8 (epitope 18-22; Covance) and 82E1 (neoepitope 1-5; IBL, Japan). While Aβ was directly detectable with antibody 82E1 (diluted 1:1000) after separating 30 μg of total protein from concentrated culture supernatants of transfected HEK cells under reducing conditions by NuPAGE (Novex, Life Technologies, Carlsbad, USA) using MES running buffer, detection of Aβ with antibody 4G8 required an IP prior the immunoblotting. For this, culture supernatants were removed 20 h after transfection and supplemented with 10 μg of antibody 4G8. After incubation for 12 h at 4°C, magnetic beads conjugated with Protein G (New England Biolabs, Frankfurt am Main, Germany) were applied according to the manufactory's instruction. Total protein of IP was separated by NuPAGE and subjected to Western blot analysis using antibody 4G8 (diluted 1:500). Horseradish peroxidase-conjugated secondary antibody was applied diluted 1:10 000. Chemiluminescence was detected using ECL advanced chemiluminescence kit (GE Healthcare Life Sciences, Freiburg, Germany).
Mass spectrometric analyses
Stably transfected HEK-mock or HEK-MT2-Myc-His cells grown in 25 cm 2 -flasks were transiently transfected with 12 μg pEXPR-Strep-APP770
ΔKPI by lipofection with Lipofectamine TM 2000 (Life Technologies) in the presence of Opti-MEM (Life Technologies) according to the manufacturer's instructions. After 24 h, Aβ was immunoprecipitated from conditioned medium with 4G8 antibody (epitope 18-22; Covance) and magnetic beads conjugated with Protein G (New England Biolabs, Frankfurt am Main, Germany). Protein G magnetic beads were washed twice in phosphate-buffered saline (PBS) and twice with ammonium acetate. Aβ was eluted twice with 300 μl of 50% acetic acid and vacuum dried.
In an alternative experiment 1 μg synthetic Aβ(1-42) (H1368; Bachem) was incubated overnight at 37°C with 1 μg recombinant Histagged matriptase-2 in a total volume of 10 μl. His-tagged matriptase-2 was purified as described previously ( Figure S4A ) (Jäckle et al., 2015) .
The samples were subsequently analyzed by the Mass Spectrometry Unit, Institute of Biochemistry and Molecular Biology, University of Bonn. For MALDI-TOF measurements peptide solutions were desalted on Zip-Tip C18 (Merck Chemicals GmbH, Darmstadt, Germany), eluates were dried in a vacuum concentrator and redissolved in 4 μl TFA 0.1%. 1 μl was mixed with 1 μl matrix solution (ACN 50%, TFA 0.1%) on a ground steel target and analyzed in reflectron mode MALDI-TOF (Autoflex III, Bruker Daltonik GmbH, Bremen, Germany). Data were processed and visualized with FlexAnalysis Software (Bruker Daltonik).
For LC-MS analysis peptides were dissolved in 8 μl 0.1% trifluoroacetic acid. 1.5 μl were injected onto a C18 trap column (20 mm length, 100 μm inner diameter) coupled to a C18 analytical column (200 mm length, 75 μm inner diameter), made in house with 1.9 μm ReproSil-Pur 120 C18-AQ particles (Dr. Maisch, Ammerbuch, Germany). Solvent A was 0.1% formic acid. Peptides were separated during a linear gradient from 4% to 40% solvent B (80% acetonitrile, 0.1% formic acid) within 80 min at a flow rate of 320 nl/min. The nanoHPLC was coupled online to an LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). Ions between 330 and 1600 m/z were scanned in the Orbitrap detector with a resolution of 30,000 (maximum fill time 400 ms, AGC target 10 6 ). The 25 most intense precursor ions (threshold intensity 5000) were subjected to collision induced dissociation and fragments analyzed in the linear ion trap. Fragmented peptide ions were excluded from repeat analysis for 15 s. Raw data processing and analysis of database searches were performed with Proteome Discoverer software 2.0.0.802 (Thermo Fisher Scientific). Peptide identification was done with an in house Mascot server version 2.5.1 (Matrix Science Ltd, London, UK). Data were searched against human sequences from SwissProt (release 2015_03). Precursor ion m/z tolerance was 10 ppm, fragment ion tolerance 0.6 Da. Tryptic peptides were searched with up to two missed cleavages. Low scoring spectrum matches were searched again with semitryptic specificity with up to one missed cleavage. Oxidation (Met) and acetylation (protein N-terminus) were set as dynamic modifications. Mascot results from searches against SwissProt were sent to the percolator algorithm version 2.05 (Kall et al., 2008) as implemented in Proteome Discoverer. Only proteins with two peptides (maximum posterior error probability 1%) were considered identified.
Statistical analysis
Statistical analysis was performed with standard statistical functions of GraphPad Prism using a two-tailed t-test. If not stated otherwise, all values represent means±SD. The error probability was set at p < 0.05 (indicated in Figures by *) , p < 0.01 (**) or p < 0.001 (***). 
